Izvorni znanstveni članak
Treatment for male breast cancer – 30-year experience at The University Hospital for Tumors In Zagreb, Croatia
Mladen Stanec
; Department of Surgical Oncology, University Hospital for Tumors, Zagreb, Croatia
Stjepan Juzbašić
; Department of Surgical Oncology, University Hospital for Tumors, Zagreb, Croatia
Miroslav Lesar
; Department of Surgical Oncology, University Hospital for Tumors, Zagreb, Croatia
Danko Vrdoljak
; Department of Surgical Oncology, University Hospital for Tumors, Zagreb, Croatia
Ivan Milas
; Department of Surgical Oncology, University Hospital for Tumors, Zagreb, Croatia
Nenad Nola
; Department of Surgical Oncology, University Hospital for Tumors, Zagreb, Croatia
Andrej Roth
; Department of Surgical Oncology, University Hospital for Tumors, Zagreb, Croatia
Dubravka Mužina
; Department of Surgical Oncology, University Hospital for Tumors, Zagreb, Croatia
Dubravka Krleža-Supić
; Department of Anesthesiology, University Hospital for Tumors, Zagreb,Croatia
Miroslav Banović
; Department of Transfusion Medicine and Hemostasis, University Hospital for Tumors, Zagreb, Croatia
Sažetak
The study includes records of male patients treated for breast cancer at the Department of Surgery, University Hospital for Tumors, Zagreb, Croatia between 1969 and 1999. In that period, 71 male patients were treated for primary carcinoma of the breast; one of them had cancer in both breasts. The follow-up included the interval between disease onset and diagnosis, age, stage, localization, histologic finding, hormone receptors, metastases and treatment options. The mean age at cancer onset was 62 years, or about 11 years later than in female patients. Age, axillary lymph node status, tumor grade and tumor size were shown to be significant prognostic factors. Primary treatment choice depended upon clinical status of the tumor, age and patient's general condition. The statistical significance was shown between a stage estimated at presentation and stage according to TNM classification (2 = 43.99; d.f. =6; p < 0.01), survival duration by TNM (2 = 45.27; d.f. = 15; p = 0.00007), and between treatment type and duration of survival (2 = 45.26; d.f. = 30; p = 0.04). The correlation bewteen the patient's age and duration of survival, anamnesis and survival, and hormone receptors and survival was not statistically significant.
Ključne riječi
breast cancer; male; treatment
Hrčak ID:
281782
URI
Datum izdavanja:
3.12.2003.
Posjeta: 482 *